GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (AMEX:IGC) » Definitions » Gross Margin %

IGC (IGC Pharma) Gross Margin % : 48.06% (As of Sep. 2024)


View and export this data going back to 2006. Start your Free Trial

What is IGC Pharma Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. IGC Pharma's Gross Profit for the three months ended in Sep. 2024 was $0.20 Mil. IGC Pharma's Revenue for the three months ended in Sep. 2024 was $0.41 Mil. Therefore, IGC Pharma's Gross Margin % for the quarter that ended in Sep. 2024 was 48.06%.


The historical rank and industry rank for IGC Pharma's Gross Margin % or its related term are showing as below:

IGC' s Gross Margin % Range Over the Past 10 Years
Min: 2.58   Med: 12.91   Max: 56.21
Current: 56.21


During the past 13 years, the highest Gross Margin % of IGC Pharma was 56.21%. The lowest was 2.58%. And the median was 12.91%.

IGC's Gross Margin % is ranked worse than
54.35% of 747 companies
in the Biotechnology industry
Industry Median: 60.58 vs IGC: 56.21

IGC Pharma had a gross margin of 48.06% for the quarter that ended in Sep. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for IGC Pharma was 105.10% per year.


IGC Pharma Gross Margin % Historical Data

The historical data trend for IGC Pharma's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma Gross Margin % Chart

IGC Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.82 12.58 48.87 48.52 54.50

IGC Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.79 65.20 57.97 59.93 48.06

Competitive Comparison of IGC Pharma's Gross Margin %

For the Biotechnology subindustry, IGC Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IGC Pharma's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's Gross Margin % distribution charts can be found below:

* The bar in red indicates where IGC Pharma's Gross Margin % falls into.



IGC Pharma Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

IGC Pharma's Gross Margin for the fiscal year that ended in Mar. 2024 is calculated as

Gross Margin % (A: Mar. 2024 )=Gross Profit (A: Mar. 2024 ) / Revenue (A: Mar. 2024 )
=0.7 / 1.345
=(Revenue - Cost of Goods Sold) / Revenue
=(1.345 - 0.612) / 1.345
=54.50 %

IGC Pharma's Gross Margin for the quarter that ended in Sep. 2024 is calculated as


Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=0.2 / 0.412
=(Revenue - Cost of Goods Sold) / Revenue
=(0.412 - 0.214) / 0.412
=48.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


IGC Pharma  (AMEX:IGC) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

IGC Pharma had a gross margin of 48.06% for the quarter that ended in Sep. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


IGC Pharma Gross Margin % Related Terms

Thank you for viewing the detailed overview of IGC Pharma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


IGC Pharma Business Description

Traded in Other Exchanges
Address
10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Executives
James P Moran director 914 SPRING HILL ROAD, MCLEAN VA 22102
John Edward Lynch director 14 PARK AVENUE, REHOBOTH BEACH DE 19971
Richard K Prins director
Ram Mukunda director, officer: Exec. Chairman & CEO
Claudia Grimaldi officer: Vice president and PFO PO BOX 60642, POTOMAC MD 20859
Rohit Goel officer: Manager & PAO PO BOX 60642, POTOMAC MD 20859
John Cherin officer: CFO, Treasurer and PAO 662 LIVE OAK DRIVE, MCLEAN VA 22101
Shu Kwong Ngai director, officer: Interim CFO 4336 MONTGOMERY AVENUE, BETHESDA MD 20814
Ranga C Krishna director 330 THORNTON ROAD, ENGLEWOOD X1 07631
Sudhakar V Shenoy director 10411 MOTOR CITY DRIVE, BETHESDA MD 20817
Suhail Nathani director INDIA GLOBALIZATION CAPITAL, INC., 4336 MONTGOMERY AVE., BETHESDA MD 20814
Nisswa Acquisition Master Fund Ltd. 10 percent owner C/O MAPLES CORPORATE SVCS LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Smith Edward B Iii 10 percent owner C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
Ag Ubs 10 percent owner 600 WASHINGTON BLVD., STAMFORD CT 06901
Pine River Master Fund Ltd. 10 percent owner C/O PINE RIVER CAPITAL MANAGEMENT L.P., 601 CARLSON PARKWAY, 7TH FLOOR, MINNETONKA MN 55305

IGC Pharma Headlines

From GuruFocus